Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.

Oncotarget · 2016 · PMC5226611 · PMID 27409420

Europe PMC DOI

hedged sentence

0.1720

closest p · 3.4× alpha

0.1720

boldest claim

The sentences

showed a trendP =0.172not close (p > 0.1)

OS2 showed a trend of benefit in group A without statistical significance (10.5 months versus 6.5 months, P =0.172), while median OS was 22 months in group A compared with 16 months in group B, P =0.048 (Figure 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.